Amgen ends marketing agreement with GSK for osteoporosis drug

April 3 (Reuters) - Amgen Inc said it was ending anagreement with GlaxoSmithKline Plc, under which theBritish company marketed Amgen's postmenopausal osteoporosisdrug in some regions outside the United States.

Amgen said it would take over the marketing of the drug inareas under the agreement, including the European Union,Switzerland, Norway, Russia and Mexico, no later than Dec. 31.(http://link.reuters.com/cax28v)

The termination of the deal, signed in July 2009, will notaffect GSK's marketing activities in Australia, Amgen said in aregulatory filing.

The company said it would pay GSK $275 million over the restof the year and reimburse the British drugmaker $15 million forcosts incurred during the transition period. (Reporting By Vrinda Manocha in Bangalore; Editing by SimonJennings)